Authors

From Advantage to Essential: How Daily Data & AI Alerts Transform Commercial Functions

The importance for pharma in recognizing integrated data sources as necessary infrastructure—not just a competitive edge.

Realtime Electronic Data Capture at Investigator Sites: Laboratory Data and Beyond

Pharma Forecasting: Key Markets Investors Can’t Ignore

The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.

Maintaining Supply Chain Resiliency, No Matter the Circumstances

The formula for future-proofing pharmaceutical networks to withstand any disruption.

The 8 Market Access Performance Metrics You Should Be Tracking

This guide offers an in-depth analysis of the essential KPIs that market access teams should track to measure success particularly across speed of access, breadth of access, and price performance. It includes real-life use cases and practical steps on how to get started.

Pharmaceutical Risks in the Strait of Hormuz

The ongoing volatility in the Middle East and disruption risks tied to the Strait of Hormuz are exposing a broader but often underappreciated vulnerability in global pharmaceuticals.

Translating ‘Digital-First’ to Commercial Success

Why a fundamental rethinking of how manufacturers engage with healthcare providers, payers, and patients is necessary in today's pharma landscape.

Approaching Agentic AI Strategically: Life Sciences Data Utilization

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful progress in how data insights inform commercial decision-making.

FDA Clears Every-8-Week Lebrikizumab Maintenance Dosing in Atopic Dermatitis

Eli Lilly and Company notes that the approval of an every-8-week maintenance dose of lebrikizumab offers sustained atopic dermatitis control with fewer annual injections.

The Long-Term Outlook for MFN Pricing: Far-Reaching Issues and Considerations

An analysis of pricing data for 12 high-revenue drugs from Medicare Part B and Part D compares US wholesale acquisition costs with the lowest prices in reference countries under the most-favored nation model.

The Leap Forward: Practical Gains for Pharma AI Use

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.

The Business Case for Employer-Based GLP-1 Coverage

Chief commercial officer Susan Thomas from LucyRx explains why coverage isn’t a one-size-fits all problem.

Biopharma Needs a Health System Strategy to Secure Optimal Market Access

In today’s pharmaceutical market access landscape, payers are not the sole decision-makers in utilization management development.

Rethinking Audience Modeling: AI, Regulations, & More

The intersection of artificial intelligence and direct-to-consumer advertising presents unprecedented opportunities and evolving challenges as regulations and technologies reshape the biopharma landscape.

The Leap Forward: Practical Gains for Pharma AI Use

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.

Artificial Intelligence Makes Possible a Multiomic Approach in Oncology Drug Discovery

While challenges remain, AI is accelerating the process by enabling researchers to identify and design new drug candidates more quickly and efficiently with applications in target discovery, structure prediction, and drug optimization.

Using AI to Predict Launch Success

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global Investment

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

Stop Losing Patients at the Gate: The 24-Hour Window That Makes or Breaks Your Entire Hub Program

Pioneering pharma’s next era: What will define the leaders of 2035?

Measuring Pharma’s Trust Performance

The core building blocks of trust must be operationalized for pharma companies to strengthen their social contract, deliver business value, and improve patients’ quality of life.

Rethinking Pharma's Go-to-Market Formula

Mike Petroutsas, president and head of U.S. commercial at Astellas, explores the importance of insight-driven commercialization in reshaping how manufacturers engage patients, physicians and the broader healthcare ecosystem.

How Agentic AI Is Reshaping the Launch Playbook for Pharma

The agentic model is emerging as a strategic tool to compress analysis timelines, coordinate cross-functional teams and surface competitive intelligence in real time.

Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma

Your Phase III Clinical Protocol Is Your Initial Product Launch

How demand-driven development will help new products be more successful.

Actionable Insights at the Point of Care: A New Era in Provider Engagement

How pharma marketers can time brand messages to prescribers when it matters most.

Why Breakthrough Cell and Gene Therapies Still Fail at the Finish Line

As FDA complete response letters continue to impact nearly half of cell and gene therapy submissions, manufacturing strategy and process design are emerging as the industry’s most persistent regulatory vulnerabilities.